Unregistered Sales of Equity Securities and Use of Proceeds
−Removed: Issuer purchases of equity securities for the three months ended September 30, 2024 were as follows:
+Added: Issuer purchases of equity securities for the three months ended March 31, 2025 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
3 unchanged sentences
Average Price
−Removed: Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate Dollar Value of Shares
+Added: Share Total Number of Shares
+Added: Purchased as Part of
+Added: Publicly Announced Plans or
+Added: Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
−Removed: July 1 - July 31
−Removed: 880,451 $126.08 880,451 $3,217
−Removed: August 1 - August 31
−Removed: 1,391,425 $114.53 1,391,425 $3,058
−Removed: September 1 - September 30
−Removed: 1,496,936 $116.19 1,496,936 $2,884
+Added: January 1 - January 31 2,424,000 $98.65 2,424,000 $12,162
+Added: February 1 - February 28 4,182,640 $88.23 4,182,640 $11,793
+Added: March 1 - March 31 6,002,753 $92.61 6,002,753 $11,237
Total 12,609,393 $92.32 12,609,393
(1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury.
+Added: In January 2025, the Board of Directors approved a plan to purchase up to an additional $10 billion of Merck’s common stock for its treasury.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.